Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
02 2020
Historique:
received: 25 09 2019
revised: 08 11 2019
accepted: 09 12 2019
pubmed: 18 12 2019
medline: 19 3 2021
entrez: 18 12 2019
Statut: ppublish

Résumé

Our aim was to analyze the prevalence of multidrug-resistant bacterial infections in lung transplant donors and to evaluate its influence on donor-derived bacterial infections. We conducted a retrospective study of adult patients who underwent lung transplantation (2013-2016) at our hospital. Donor-derived bacterial infection was defined as the isolation of the same bacteria with identical antibiotic susceptibility patterns in the recipient and the perioperative cultures from the donor during the first month posttransplantation. We utilized a preventive antibiotic strategy adapted to the bacteria identified in donor cultures using systemic and nebulized antibiotics. 252 lung transplant recipients and 243 donors were included. In 138/243 (56.8%) donors, one bacterial species was isolated from at least one sample; graft colonization (118/243; 48.6%), blood cultures (5/243; 2.1%) and the contamination of preservation fluids (56/243; 23%). Multidrug-resistant bacteria were isolated from 12/243 (4.9%) donors; four Enterobacterales, four Stenotrophomonas maltophilia, three Pseudomonas aeruginosa and one methicillin-resistant Staphylococcus aureus. There was no transmission of these multidrug-resistant bacteria. Donor-derived infections, primarily tracheobronchitis due to non-MDR bacteria, were diagnosed in 7/253 (2.9%) recipients, with good clinical outcomes. The lungs of donors colonized with multidrug-resistant bacteria may be safely used when recipients receive prompt tailored antibiotic treatment.

Identifiants

pubmed: 31843689
pii: S0163-4453(19)30378-0
doi: 10.1016/j.jinf.2019.12.006
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-196

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest.

Auteurs

Eleonora Bunsow (E)

Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain.

Ibai Los-Arcos (I)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: ilosarco@vhebron.net.

María Teresa Martin-Gómez (MT)

Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Irene Bello (I)

Thoracic Surgery Deparment, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Teresa Pont (T)

Transplant Coordination Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Cristina Berastegui (C)

Lung Transplant Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Ricard Ferrer (R)

Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Xavier Nuvials (X)

Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

María Deu (M)

Thoracic Surgery Deparment, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Maddalena Peghin (M)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain.

Juan José González-López (JJ)

Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain; Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Mayli Lung (M)

Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain; Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Antonio Román (A)

Lung Transplant Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Joan Gavaldà (J)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain.

Oscar Len (O)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH